VSF-173
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Excessive Somnolence
Conditions
Excessive Somnolence
Trial Timeline
— → —
NCT ID
NCT00467441About VSF-173
VSF-173 is a phase 2 stage product being developed by Vanda Pharmaceuticals for Excessive Somnolence. The current trial status is completed. This product is registered under clinical trial identifier NCT00467441. Target conditions include Excessive Somnolence.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00467441 | Phase 2 | Completed |
Competing Products
8 competing products in Excessive Somnolence
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Placebo + PF-03654746 | Pfizer | Phase 2 | 51 |
| JZP-110 | Jazz Pharmaceuticals | Phase 2 | 49 |
| Solriamfetol + Placebo | Axsome Therapeutics | Approved | 82 |
| Solriamfetol 150 MG + Placebo | Axsome Therapeutics | Phase 3 | 74 |
| Solriamfetol 150 mg + Solriamfetol 300 mg + Placebo | Axsome Therapeutics | Phase 3 | 74 |
| Solriamfetol Oral Tablet + Placebo | Axsome Therapeutics | Approved | 82 |
| Fibrin Sealant Grifols + EVICEL | Grifols | Phase 3 | 74 |
| ORX142 Tablets | Centessa Pharmaceuticals | Phase 1 | 28 |